BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 28566530)

  • 1. Rationale for the development of alternative forms of androgen deprivation therapy.
    Kumari S; Senapati D; Heemers HV
    Endocr Relat Cancer; 2017 Aug; 24(8):R275-R295. PubMed ID: 28566530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.
    Liu S; Kumari S; Hu Q; Senapati D; Venkadakrishnan VB; Wang D; DePriest AD; Schlanger SE; Ben-Salem S; Valenzuela MM; Willard B; Mudambi S; Swetzig WM; Das GM; Shourideh M; Koochekpour S; Falzarano SM; Magi-Galluzzi C; Yadav N; Chen X; Lao C; Wang J; Billaud JN; Heemers HV
    Elife; 2017 Aug; 6():. PubMed ID: 28826481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
    Biron E; Bédard F
    J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
    Wang G; Sadar MD
    J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
    Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
    PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention.
    Dahiya UR; Heemers HV
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The androgen/androgen receptor axis in prostate cancer.
    Bluemn EG; Nelson PS
    Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor signaling regulates DNA repair in prostate cancers.
    Polkinghorn WR; Parker JS; Lee MX; Kass EM; Spratt DE; Iaquinta PJ; Arora VK; Yen WF; Cai L; Zheng D; Carver BS; Chen Y; Watson PA; Shah NP; Fujisawa S; Goglia AG; Gopalan A; Hieronymus H; Wongvipat J; Scardino PT; Zelefsky MJ; Jasin M; Chaudhuri J; Powell SN; Sawyers CL
    Cancer Discov; 2013 Nov; 3(11):1245-53. PubMed ID: 24027196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
    Elbanna M; Heemers HV
    Discov Med; 2014 May; 17(95):267-74. PubMed ID: 24882718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
    Chatterjee B
    Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor structural and functional elements: role and regulation in prostate cancer.
    Dehm SM; Tindall DJ
    Mol Endocrinol; 2007 Dec; 21(12):2855-63. PubMed ID: 17636035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel secondary hormonal therapy in advanced prostate cancer: an update.
    Van Allen EM; Ryan CJ
    Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation.
    Brown NE; Paluch AM; Nashu MA; Komurov K; Waltz SE
    Neoplasia; 2018 Sep; 20(9):917-929. PubMed ID: 30121008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer.
    Shiota M; Song Y; Takeuchi A; Yokomizo A; Kashiwagi E; Kuroiwa K; Tatsugami K; Uchiumi T; Oda Y; Naito S
    J Urol; 2012 Feb; 187(2):707-14. PubMed ID: 22177207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
    Culig Z; Santer FR
    Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor: past, present and future.
    Schmidt LJ; Tindall DJ
    Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
    Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
    Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of androgen receptor targeted therapy for advanced prostate cancer.
    Wong YN; Ferraldeschi R; Attard G; de Bono J
    Nat Rev Clin Oncol; 2014 Jun; 11(6):365-76. PubMed ID: 24840076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.